With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now.
Pixabay/Public Domain
Highlighting the SL-325’s Phase 1 readout, expected in Q2 2026, H.C. Wainwright’s Joseph Pantginis reiterated a “Hold” rating on Shattuck Labs, Inc. on November 7, 2025. The analyst believes the drug holds significant clinical potential, boosting the analyst’s confidence. The drug remains a key growth catalyst, with DR3-based bispecific antibodies expected to provide longer-term upside. Pantginis also cited the company’s solid financial position as visible through its cash and investments balance of $86.10 million. Thus, the analyst sees a balanced risk profile for the company, with SL-325 remaining central to the investment case.
Meanwhile, Shattuck Labs, Inc. announced its third-quarter 2025 results on November 6, 2025. The company, still in its development stage, noted R&D declining to $7.60 million, while G&A expenses totaled $4.10 million. Reflecting disciplined execution, Shattuck Labs reaffirmed advancement of the Phase 1 SL-325 trial. It also reported continued progress toward selecting a bispecific candidate in 2026. With a healthy cash balance, the company looks well-positioned to advance the drug into Phase 2 trials. Net loss for the quarter was $10.1 million, or $0.14 per basic and diluted share.
Shattuck Labs, Inc. focuses on developing novel therapies for autoimmune and inflammatory diseases. Its SL-325 drug aims for a complete blockade of the validated DR3/TL1A pathway.s
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.
